Grandeur Peak Global Advisors LLC Invests $470,000 in STAAR Surgical (NASDAQ:STAA)

Grandeur Peak Global Advisors LLC bought a new stake in STAAR Surgical (NASDAQ:STAA - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm bought 19,340 shares of the medical instruments supplier's stock, valued at approximately $470,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in STAA. FMR LLC lifted its position in shares of STAAR Surgical by 79.3% during the 3rd quarter. FMR LLC now owns 7,092 shares of the medical instruments supplier's stock worth $263,000 after buying an additional 3,136 shares during the last quarter. HighTower Advisors LLC bought a new position in shares of STAAR Surgical in the third quarter worth about $336,000. State Street Corp lifted its holdings in shares of STAAR Surgical by 0.5% in the third quarter. State Street Corp now owns 1,940,567 shares of the medical instruments supplier's stock worth $72,092,000 after acquiring an additional 10,430 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of STAAR Surgical in the 3rd quarter valued at approximately $508,000. Finally, Barclays PLC grew its holdings in shares of STAAR Surgical by 349.4% during the 3rd quarter. Barclays PLC now owns 91,707 shares of the medical instruments supplier's stock valued at $3,406,000 after purchasing an additional 71,301 shares during the last quarter. 96.70% of the stock is currently owned by institutional investors and hedge funds.

STAAR Surgical Stock Down 4.3 %

STAAR Surgical stock traded down $0.75 during mid-day trading on Tuesday, hitting $16.52. 759,185 shares of the stock were exchanged, compared to its average volume of 790,344. The stock has a market capitalization of $814.85 million, a price-to-earnings ratio of -40.29 and a beta of 0.75. STAAR Surgical has a 12 month low of $13.50 and a 12 month high of $49.86. The firm's fifty day simple moving average is $17.40 and its two-hundred day simple moving average is $23.74.

Remove Ads

Insider Buying and Selling

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. bought 259,616 shares of the stock in a transaction on Wednesday, February 12th. The stock was acquired at an average cost of $14.96 per share, for a total transaction of $3,883,855.36. Following the completion of the acquisition, the insider now owns 11,137,623 shares in the company, valued at $166,618,840.08. This trade represents a 2.39 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Insiders bought 1,750,802 shares of company stock valued at $28,584,295 over the last quarter. Insiders own 1.00% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Stephens restated an "equal weight" rating and issued a $17.00 target price on shares of STAAR Surgical in a research report on Tuesday, March 18th. Stifel Nicolaus cut their price objective on STAAR Surgical from $38.00 to $20.00 and set a "buy" rating on the stock in a report on Wednesday, February 12th. Mizuho cut STAAR Surgical from an "outperform" rating to a "neutral" rating and lowered their target price for the stock from $45.00 to $17.00 in a report on Wednesday, February 12th. Piper Sandler cut their price target on STAAR Surgical from $40.00 to $16.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 12th. Finally, BTIG Research cut STAAR Surgical from a "buy" rating to a "neutral" rating in a report on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $25.29.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.